Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients Article

Mian, S, Ugurel, S, Parkinson, E et al. (2005). Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients . JOURNAL OF CLINICAL ONCOLOGY, 23(22), 5088-5093. 10.1200/JCO.2005.03.164

Open Access International Collaboration

cited authors

  • Mian, S; Ugurel, S; Parkinson, E; Schlenzka, I; Dryden, I; Lancashire, L; Ball, G; Creaser, C; Rees, R; Schadendorf, D

sustainable development goals

authors

publication date

  • August 1, 2005

published in

keywords

  • AMERICAN JOINT COMMITTEE
  • BIOMARKERS
  • BLOOD
  • BREAST-CANCER
  • IDENTIFICATION
  • INHIBITING ACTIVITY
  • Life Sciences & Biomedicine
  • MALIGNANT-MELANOMA
  • Oncology
  • PATTERNS
  • PROSTATE-CANCER
  • PROTEIN
  • Science & Technology

Digital Object Identifier (DOI)

publisher

  • AMER SOC CLINICAL ONCOLOGY

start page

  • 5088

end page

  • 5093

volume

  • 23

issue

  • 22